ad image

Gene Editing

1 / 2
Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics
RNA

Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

PAO-25-30-24Mar 21, 2025
Five Small Biotechs to Watch: March 2025
Small Biotechs

Five Small Biotechs to Watch: March 2025

David Alvaro, Ph.D.

Pharma's Almanac

PAO-02-25-NI-06Feb 28, 2025
Orsini Healthcare
CASGEVY

Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy

Orsini Healthcare

PR-11-24-NI-103Nov 15, 2024
The Groundbreaking Potential of CRISPR Gene Editing
CRISPR

The Groundbreaking Potential of CRISPR Gene Editing

Olivia Newton-John Cancer Research Institute

PAO-10-24-RTM-09Nov 05, 2024
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.

Touchlight

PAO-10-24-CL-01Sep 30, 2024
Lipid Technology for Delivery of Gene-Editing Therapies
Lipid Nanoparticle Development

Lipid Technology for Delivery of Gene-Editing Therapies

Stephen Burgess, Ph.D.

Croda Pharma

PAO-11-022-CL-18Jan 17, 2023
Antibiotic Resistance: Advances in Understanding and Drug Development
Antibiotic Resistance

Antibiotic Resistance: Advances in Understanding and Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-022-NI-07Oct 11, 2022
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
mRNA

Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-10-022-NI-02Oct 11, 2022
Gladstone Institutes
CRISPR Research Innovation

A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors

Gladstone Institutes

PR-M08-22-05Aug 25, 2022
U.S. Food & Drug Administration
Regulatory

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

U.S. Food & Drug Administration

PR-M03-22-03Mar 07, 2022
Prime Medicine
Gene Editing

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

Prime Medicine

PA852Jul 16, 2021
Enabling Gene-Edited hMSCs with a Fit-for-Purpose Transduction Agent
Gene Editing

Enabling Gene-Edited hMSCs with a Fit-for-Purpose Transduction Agent

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-21-CL-06Jul 15, 2021
Vertex
Collaboration

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing

Vertex

PR-M04-21-024Apr 22, 2021
Enhancing Human Gut Tissue Models through Gene Editing
Gene Editing

Enhancing Human Gut Tissue Models through Gene Editing

Scott Magness, Ph.D.

Altis Biosystems

PAO-11-20-CL-03Nov 30, 2020
CRISPR RNPs and the Future of Cell and Gene Therapy
CRISPR RNPs

CRISPR RNPs and the Future of Cell and Gene Therapy

Thomas Lynch, Ph.D.

Aldevron

PAP-Q3-20-CL-002Sep 29, 2020
Slow Progress and a Shaky Start—What’s Next for Gene Therapy?
Gene Therapy

Slow Progress and a Shaky Start—What’s Next for Gene Therapy?

Nigel Walker

Nice Insight

PAP-Q4-19-NI-001Dec 06, 2019
CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway
CRISPR-Cas9

CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway

Lydia Michaut

BioAgilytix

PAP-Q4-19-CL-011Dec 06, 2019
CRISPR Gene Editing of Babies Could Take Place in Russia
CRISPR

CRISPR Gene Editing of Babies Could Take Place in Russia

Emilie Branch

Pharma's Almanac

PAO-M06-19-NI-021Jun 21, 2019
China to Introduce Regulations on Gene Editing
Gene Editing

China to Introduce Regulations on Gene Editing

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M05-19-NI-031May 29, 2019
The University of California
CRISPR-Cas9

University of California Granted New CRISPR-Cas9 Patent, Extending its Patent Portfolio for Genome Editing

The University of California

PR-M03-19-NI-040Mar 14, 2019
1 / 2